Y-mAbs Therapeutics (YMAB)
YMAB
Pediatric Oncology
BiotechSign Signal Grade
C
Signal Grade
62.5/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Clinical Activity
100
Pipeline Overview
- Therapeutic Focus
- Pediatric Oncologysrc
Clinical Trial Activity
12
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
4 Phase 1, 8 Phase 2
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Y-mAbs Therapeutics.
Full YMAB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.